替尔泊肽进医保,中国GLP-1的竞争彻底变天!

健识局
Dec 08

12月7日,礼来中国总裁德赫兰出现在“2025创新药高质量发展大会”现场,作为外资企业代表做了主题演讲。礼来是今年国家医保谈判的大赢家之一,主力产品替尔泊肽顺利纳入医保目录,适应症为2型糖尿病的治疗,成为继司美格鲁肽之后,第二个进入中国医保市场的进口GLP-1大热药物。今年11月初,德赫兰亲自带队参加替尔泊肽等产品的医保谈判,可见对中国市场重视程度和志在必得的态度。另一款国产长效GLP-1,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10